Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04188197 · ClinicalTrials.gov registry record · NA
Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes
A NA study, sponsored by Rose Research Center.
- Completed
- Registry status
- NA
- Development phase
- 50
- Enrollment target
NCT04188197 is a NA study that has completed, run by Rose Research Center. The registered enrollment target is 50 participants.
The verdict
NCT04188197, a NA study, has completed, sponsored by Rose Research Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
Study Summary
This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked. This procedure is predicted to accomplish three goals: 1) the rewarding effects of CC will be disrupted because subjects will already have attained fairly high peak nicotine concentrations immediately before smoking the cigarette. This reduces the rewarding effect of smoking, in part from receptor desensitization that occurs following nicotine exposure, which reduces the response to a subsequent dose of nicotine, and in part from satiating the drive to smoke; 2) the use of the JUUL will become associated with the same cues that elicit smoking, thereby promoting the substitution of JUUL use for CC use; and 3) ad libitum nicotine intake from the JUUL and its rewarding effects will be maximized because, unlike CC, they will be experienced after a period of nicotine deprivation. Thus, despite a lower per-puff nicotine dose relative to CC, the pharmacologic impact and reinforcing effect will be maximized. The study will evaluate two flavors (Mint and Virginia Tobacco), randomly assigned, to determine if flavor assignment (similar to the subjects' usual brand of CC or different than the subjects usual brand CC) has an effect on the success of this reconditioning procedure.
Interventions
- OTHER JUUL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2021-06-22 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04188197
The ClinicalTrials.gov registry entry for NCT04188197 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rose Research Center, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JUUL is the first listed.
NCT04188197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04188197 about?
NCT04188197 is a clinical study titled "Assisting Smokers to Switch to a JUUL E-Cigarette by Devaluing Combustible Cigarettes". This study will evaluate a reward devaluation strategy in which smokers use the JUUL e-cigarette immediately before any combustible cigarettes (CCs) are smoked. This procedure is predicted to accomplish three goals: 1) the rewarding effects of CC will be disrupted because subjects will already have ...
What is the current status of trial NCT04188197?
This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2019-08-26. Estimated completion is 2021-06-22.
What interventions are being tested in trial NCT04188197?
The interventions under investigation include: JUUL (OTHER).
Who is sponsoring clinical trial NCT04188197?
This trial is sponsored by Rose Research Center, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.